Ocugen Inc (OCGN)stock report

Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Market Cap:30.5M; Shares Outstanding:52.6M; Short Interest: 23.30%;
no financial data available

EPS and Sales:

Insider Transactions:

Institution Ownership:

Total institutions: 28,no change
Shares hold: 650.8k shares. no change
shares% hold: 4.07%,no change

Analyst Ratings:

Leave a Reply